Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Diclofenac. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 5/20 | 0.97 |
| ▸ | PTGS1 known ✓ | P23219 | 2/20 | 0.97 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.97 |
| ▸ | GAA | P10253 | 1/20 | 0.97 |
| ▸ | TSHR | P16473 | 1/20 | 0.97 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.97 |
| ▸ | BLM | P54132 | 1/20 | 0.97 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.97 |
| ▸ | TTR | P02766 | 3/20 | 0.71 |
| ▸ | CXCL8 | P10145 | 3/20 | 0.71 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.71 |
| ▸ | UGT1A9 | O60656 | 1/20 | 0.71 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.71 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.71 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.71 |
| ▸ | ALB | P02768 | 1/20 | 0.71 |
| ▸ | UGT1A6 | P19224 | 1/20 | 0.71 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.71 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diclofenac SCHEMBL29385384 | 0.98 | PTGS2 (0.94) | PTGS2PTGS1CYP2C9CYP3A4GAA | |
| Diclofenac SCHEMBL8765115 | 0.98 | PTGS2 (0.94) | PTGS2PTGS1CYP2C9CYP3A4GAA | |
| Diclofenac SCHEMBL29350388 | 0.98 | PTGS2 (1.00) | PTGS2PTGS1CYP2C9CYP3A4GAA | |
| Diclofenac SCHEMBL40784 | 0.98 | PTGS2 (0.94) | PTGS2PTGS1CYP2C9CYP3A4GAA | |
| Diclofenac SCHEMBL24009 | 0.98 | PTGS2 (1.00) | PTGS2PTGS1CYP2C9CYP3A4GAA | |
| Diclofenac SCHEMBL1244510 | 0.98 | PTGS2 (1.00) | PTGS2PTGS1CYP2C9CYP3A4GAA | |
| Diclofenac SCHEMBL6509233 | 0.97 | PTGS2 (0.97) | PTGS2PTGS1CYP2C9CYP3A4GAA | |
| Diclofenac SCHEMBL21048102 | 0.97 | PTGS2 (0.97) | PTGS2PTGS1CYP2C9CYP3A4GAA | |
| Diclofenac SCHEMBL7083032 | 0.97 | PTGS2 (0.97) | PTGS2PTGS1CYP2C9CYP3A4GAA | |
| Diclofenac SCHEMBL27229363 | 0.95 | PTGS2 (0.94) | PTGS2PTGS1CYP2C9CYP3A4GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240148889-A1 | STABILIZED TRIOXACARCIN ANTIBODY DRUG CONJUGATES AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-05-09 | — | — | US | disclosed |
| US-20210338709-A1 | USES OF MODIFIED RNA ENCODING RETINALDEHYDE DEHYDROGENASE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-11-04 | — | — | US | disclosed |
| US-20200316159-A1 | SUSTAINED RELEASE COMPOSITIONS OF KAPPA-OPIOID RECEPTOR AGONIST | TITAN PHARMACEUTICALS, INC. | 2020-10-08 | — | — | US | disclosed |
| US-10639381-B2 | Trioxacarcins, trioxacarcin#antibody conjugates, and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2020-05-05 | — | — | US | disclosed |
| EP-2922575-B1 | TRIOXACARCINS, TRIOXACARCIN-ANTIBODY CONJUGATES, AND USES THEREOF | HARVARD COLLEGE (US) | 2019-06-26 | — | — | EP | disclosed |
| US-10278916-B2 | Implants for the treatment of dopamine associated states | NUPATHE INC. (US) | 2019-05-07 | — | — | US | disclosed |
| EP-3463306-A1 | SUSTAINED RELEASE COMPOSITIONS OF KAPPA-OPIOID RECEPTOR AGONIST | JT Pharmaceuticals, Inc. (US) | 2019-04-10 | — | — | EP | disclosed |
| US-20180244700-A1 | METHODS OF TREATING A FATTY ACID AMIDE HYDROLASE-MEDIATED CONDITION | INFINITY PHARMACEUTICALS, INC. | 2018-08-30 | — | — | US | disclosed |
| US-20180221504-A1 | TRIOXACARCINS, TRIOXACARCIN-ANTIBODY CONJUGATES, AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-08-09 | — | — | US | disclosed |
| US-9951089-B2 | Methods of treating a fatty acid amide hydrolase-mediated condition | INFINITY PHARMACEUTICALS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20050004080-A1 | Derivatives of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and methods of use thereof | WYETH (US) | 2005-01-06 | — | — | US | disclosed |
| WO-2004089375-A1 | IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST | TITAN PHARMACEUTICALS, INC. (US) | 2004-10-21 | — | — | WO | disclosed |
| US-6797708-B2 | ENZYME INHIBITORS SUCH AS 4-(2-(1-BENZHYDRYL-2-(2-((BENZYL-SULFONYL)AMINO)ETHYL)-5-CHLORO-1H-INDOL-3 -YL)ETHOXY) BENZOIC ACID, USED AS ANALGESICS OR ANTIINFLAMMATORY AGENTS | WYETH | 2004-09-28 | — | — | US | disclosed |
| US-20030166649-A1 | Methods for treating arthritic disorders | WYETH | 2003-09-04 | — | — | US | disclosed |
| US-20030144282-A1 | Inhibitors of cytosolic phospholipase A2 | WYETH | 2003-07-31 | — | — | US | disclosed |
| US-20030114444-A1 | [[2-(Amino-3,4-dioxo-1-cyclobuten-1-yl)amino]alkyl]-acid derivatives for the treatment of pain | WYETH | 2003-06-19 | — | — | US | disclosed |
| EP-0805684-A4 | METHODS OF ENHANCING THE THERAPEUTIC ACTIVITY OF NSAIDS AND COMPOSITIONS OF ZWITTERIONIC PHOSPHOLIPIDS USEFUL THEREIN | UNIV TEXAS (US) | 1998-08-05 | — | — | EP | disclosed |
| WO-1998013073-A1 | METHODS OF ENHANCING THE THERAPEUTIC ACTIVITY OF NSAIDs AND COMPOSITIONS OF ZWITTERIONIC PHOSPHOLIPIDS USEFUL THEREIN | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1998-04-02 | — | — | WO | disclosed |
| EP-0805684-A2 | METHODS OF ENHANCING THE THERAPEUTIC ACTIVITY OF NSAIDS AND COMPOSITIONS OF ZWITTERIONIC PHOSPHOLIPIDS USEFUL THEREIN | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1997-11-12 | — | — | EP | disclosed |
| WO-1996022780-A1 | METHODS OF ENHANCING THE THERAPEUTIC ACTIVITY OF NSAIDS AND COMPOSITIONS OF ZWITTERIONIC PHOSPHOLIPIDS USEFUL THEREIN | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 1996-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180244700-A1 | METHODS OF TREATING A FATTY ACID AMIDE HYDROLASE-MEDIATED CONDITION | FAAH, FAAH2, FASN | PTGS2 377/4885PTGS1 399/4885CYP2C9 738/4885 |
| US-20240148889-A1 | STABILIZED TRIOXACARCIN ANTIBODY DRUG CONJUGATES AND USES THEREOF | ABCB4, PCSK7, F12 | PTGS2 4570/4885PTGS1 4271/4885CYP2C9 467/4885 |
| US-10278916-B2 | Implants for the treatment of dopamine associated states | SLC6A3, DBH, COMT | PTGS2 1764/4885PTGS1 1128/4885CYP2C9 2733/4885 |
| US-20030114444-A1 | [[2-(Amino-3,4-dioxo-1-cyclobuten-1-yl)amino]alkyl]-acid derivatives for the treatment of pain | OPRD1, OPRL1, OPRK1 | PTGS2 111/4885PTGS1 116/4885CYP2C9 1576/4885 |
| US-20050004080-A1 | Derivatives of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and methods of use thereof | GRIN1, GRIN2B, GRIN3A | PTGS2 1313/4885PTGS1 727/4885CYP2C9 2039/4885 |
| US-10639381-B2 | Trioxacarcins, trioxacarcin#antibody conjugates, and uses thereof | C9, CES1, LYPLA1 | PTGS2 3887/4885PTGS1 3221/4885CYP2C9 219/4885 |
| US-20030166649-A1 | Methods for treating arthritic disorders | PLA2G12A, PLA2G4A, PLA2G4B | PTGS2 28/4885PTGS1 22/4885CYP2C9 1524/4885 |
| US-20180221504-A1 | TRIOXACARCINS, TRIOXACARCIN-ANTIBODY CONJUGATES, AND USES THEREOF | C9, CES1, LYPLA1 | PTGS2 3912/4885PTGS1 3258/4885CYP2C9 221/4885 |
| US-20200316159-A1 | SUSTAINED RELEASE COMPOSITIONS OF KAPPA-OPIOID RECEPTOR AGONIST | OPRK1, OPRL1, OPRD1 | PTGS2 1008/4885PTGS1 738/4885CYP2C9 1544/4885 |
| US-20030144282-A1 | Inhibitors of cytosolic phospholipase A2 | PLA2G4A, PLA2G4B, PLA2G4C | PTGS2 28/4885PTGS1 48/4885CYP2C9 1341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.